WO2001078754A3 - Soft tissue and bone augmentation and bulking utilizing muscle-derived progenitor cells, compositions and treatments thereof - Google Patents

Soft tissue and bone augmentation and bulking utilizing muscle-derived progenitor cells, compositions and treatments thereof Download PDF

Info

Publication number
WO2001078754A3
WO2001078754A3 PCT/US2001/012084 US0112084W WO0178754A3 WO 2001078754 A3 WO2001078754 A3 WO 2001078754A3 US 0112084 W US0112084 W US 0112084W WO 0178754 A3 WO0178754 A3 WO 0178754A3
Authority
WO
WIPO (PCT)
Prior art keywords
mdcs
soft tissue
bulking
compositions
muscle
Prior art date
Application number
PCT/US2001/012084
Other languages
French (fr)
Other versions
WO2001078754A2 (en
Inventor
Michael B Chancellor
Johnny Huard
Christopher C Capelli
Zhuqing Qu
Original Assignee
Michael B Chancellor
Johnny Huard
Christopher C Capelli
Zhuqing Qu
Univ Pittsburgh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24195003&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2001078754(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US09/549,937 external-priority patent/US7115417B1/en
Priority to JP2001576054A priority Critical patent/JP5684963B2/en
Priority to EP01924998A priority patent/EP1272204B1/en
Priority to DE60129007T priority patent/DE60129007T2/en
Priority to AU2001251599A priority patent/AU2001251599B2/en
Application filed by Michael B Chancellor, Johnny Huard, Christopher C Capelli, Zhuqing Qu, Univ Pittsburgh filed Critical Michael B Chancellor
Priority to DK01924998T priority patent/DK1272204T3/en
Priority to AU5159901A priority patent/AU5159901A/en
Priority to CA2406393A priority patent/CA2406393C/en
Priority to SI200130762T priority patent/SI1272204T1/en
Publication of WO2001078754A2 publication Critical patent/WO2001078754A2/en
Publication of WO2001078754A3 publication Critical patent/WO2001078754A3/en
Priority to HK03104760.7A priority patent/HK1052645B/en
Priority to AU2006202380A priority patent/AU2006202380B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0658—Skeletal muscle cells, e.g. myocytes, myotubes, myoblasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0658—Skeletal muscle cells, e.g. myocytes, myotubes, myoblasts
    • C12N5/0659—Satellite cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/70—Undefined extracts
    • C12N2500/80—Undefined extracts from animals
    • C12N2500/84—Undefined extracts from animals from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/50—Proteins
    • C12N2533/54—Collagen; Gelatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)

Abstract

The present invention provides muscle-derived progenitor cells (MDCs) that show long-term survival following transplantation into body tissues and which can augment soft tissue following introduction into a site of soft tissue. Also provided are methods of isolating MDCs. The invention further provides methods of using compositions comprising MDCs for the augmentation and bulking of mammalian, including human, soft tissues in the treatment of various cosmetic or functional conditions, including malformation, injury, weakness, disease, or dysfunction. The invention also relates to uses of MDCs for the treatment of cosmetic or functional conditions, including, but not limited to skeletal muscle weakness, muscular dystrophy, muscle atrophy, spasticity, myoclonus and myalgia. The invention also relates to the novel use of MDCs for the increase of skeletal muscle.
PCT/US2001/012084 2000-04-14 2001-04-12 Soft tissue and bone augmentation and bulking utilizing muscle-derived progenitor cells, compositions and treatments thereof WO2001078754A2 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
SI200130762T SI1272204T1 (en) 2000-04-14 2001-04-12 Soft tissue and bone augmentation and bulking utilizing muscle-derived progenitor cells, compositions and treatments thereof
CA2406393A CA2406393C (en) 2000-04-14 2001-04-12 Soft tissue and bone augmentation and bulking utilizing muscle-derived progenitor cells, compositions and treatments thereof
EP01924998A EP1272204B1 (en) 2000-04-14 2001-04-12 Soft tissue and bone augmentation and bulking utilizing muscle-derived progenitor cells, compositions and treatments thereof
DE60129007T DE60129007T2 (en) 2000-04-14 2001-04-12 REPRODUCTION OF SOFT AND BONE TISSUE FROM MUSCLE PREMATURE CELLS, AND RELATED COMPOSITIONS AND TREATMENT FORMS
AU2001251599A AU2001251599B2 (en) 2000-04-14 2001-04-12 Soft tissue and bone augmentation and bulking utilizing muscle-derived progenitor cells, compositions and treatments thereof
JP2001576054A JP5684963B2 (en) 2000-04-14 2001-04-12 Muscle tissue-derived progenitor cells, their compositions, and soft tissue and bone growth and thickening using treatments
DK01924998T DK1272204T3 (en) 2000-04-14 2001-04-12 Enhancement and bulking of soft tissue and bone tissue using muscle derived progenitor cells, preparations thereof and treatment thereof
AU5159901A AU5159901A (en) 2000-04-14 2001-04-12 Soft tissue and bone augmentation and bulking utilizing muscle-derived progenitor cells, compositions and treatments thereof
HK03104760.7A HK1052645B (en) 2000-04-14 2003-07-04 Soft tissue and bone augmentation and bulking utilizing muscle-derived progenitor cells, compositions and treatments thereof
AU2006202380A AU2006202380B2 (en) 2000-04-14 2006-06-02 Soft tissue and bone augmentation and bulking utilizing muscle-derived progenitor cells, compositions and treatments thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/549,937 US7115417B1 (en) 1998-05-01 2000-04-14 Soft tissue and bone augmentation and bulking utilizing muscle-derived progenito compositions, and treatments thereof
US09/549,937 2000-04-14

Publications (2)

Publication Number Publication Date
WO2001078754A2 WO2001078754A2 (en) 2001-10-25
WO2001078754A3 true WO2001078754A3 (en) 2002-04-25

Family

ID=24195003

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/012084 WO2001078754A2 (en) 2000-04-14 2001-04-12 Soft tissue and bone augmentation and bulking utilizing muscle-derived progenitor cells, compositions and treatments thereof

Country Status (13)

Country Link
US (3) US9499791B2 (en)
EP (1) EP1272204B1 (en)
JP (2) JP5684963B2 (en)
AT (1) ATE365045T1 (en)
AU (2) AU2001251599B2 (en)
CA (1) CA2406393C (en)
CY (1) CY1108090T1 (en)
DE (1) DE60129007T2 (en)
DK (1) DK1272204T3 (en)
ES (1) ES2288946T3 (en)
HK (1) HK1052645B (en)
PT (1) PT1272204E (en)
WO (1) WO2001078754A2 (en)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6485723B1 (en) 1995-02-10 2002-11-26 Purdue Research Foundation Enhanced submucosal tissue graft constructs
US6866842B1 (en) 1998-05-01 2005-03-15 University Of Pittsburgh Muscle-derived cells (MDCs) for treating muscle-or bone-related injury or dysfunction
US7115417B1 (en) 1998-05-01 2006-10-03 Chancellor Michael B Soft tissue and bone augmentation and bulking utilizing muscle-derived progenito compositions, and treatments thereof
DK1272204T3 (en) 2000-04-14 2007-09-10 Univ Pittsburgh Enhancement and bulking of soft tissue and bone tissue using muscle derived progenitor cells, preparations thereof and treatment thereof
JP4680483B2 (en) 2001-02-23 2011-05-11 ユニバーシティ オブ ピッツバーグ オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション Rapid preparation of stem cell matrix for use in the treatment and repair of tissues and organs
US20030082153A1 (en) * 2001-10-22 2003-05-01 The Government Of The United States Of America Stem cells that transform to beating cardiomyocytes
AU2003231248B2 (en) 2002-05-02 2009-03-05 Purdue Research Foundation Vascularization enhanced graft constructs
JP2005533535A (en) 2002-05-02 2005-11-10 パーデュー・リサーチ・ファウンデーション Graft composition with enhanced angiogenesis
CA2484614A1 (en) 2002-05-02 2003-11-13 Cook Biotech Incorporated Cell-seeded extracellular matrix grafts
EP2103684A1 (en) 2002-05-02 2009-09-23 Purdue Research Foundation Vascularisation enhanced graft constructs
CN1655834A (en) * 2002-05-06 2005-08-17 贝克顿·迪金森公司 Method and device for controlling drug pharmacokinetics
WO2004017972A1 (en) * 2002-08-23 2004-03-04 Law Peter K Biologic skin repair and enhancement
WO2004096245A2 (en) * 2003-04-25 2004-11-11 The University Of Pittsburgh Muscle derived cells (mdcs) for promoting and enhancing nerve repair and regeneration
EP1691852A2 (en) 2003-11-10 2006-08-23 Angiotech International AG Medical implants and fibrosis-inducing agents
WO2005070439A1 (en) 2004-01-09 2005-08-04 Regeneration Technologies Inc. Implant comprising a human muscle tissue matrix
WO2005070328A1 (en) 2004-01-09 2005-08-04 Regeneration Technologies, Inc. Muscle-based grafts/implants
US7001430B2 (en) 2004-01-09 2006-02-21 Regeneration Technologies, Inc. Matrix composition for human grafts/implants
DE602006014534D1 (en) * 2005-05-30 2010-07-08 Commw Scient Ind Res Org PREPARATION AND USE OF BASAL MEMBRANE PARTICLES
US20070065415A1 (en) * 2005-09-16 2007-03-22 Kleinsek Donald A Compositions and methods for the augmentation and repair of defects in tissue
US7815923B2 (en) 2005-12-29 2010-10-19 Cook Biotech Incorporated Implantable graft material
JP5395672B2 (en) * 2006-11-28 2014-01-22 ユニバーシティー オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケーション Muscle-derived cells for treating cardiac pathology and methods for making and using the same
AU2007334331B2 (en) 2006-12-18 2014-05-29 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Muscle derived cells for the treatment of gastro-esophageal pathologies and methods of making and using the same
US20100158875A1 (en) 2006-12-18 2010-06-24 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Muscle derived cells for the treatment of gastro-esophageal pathologies and methods of making and using the same
JP5425641B2 (en) 2007-01-11 2014-02-26 ユニバーシティー オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケーション Muscle-derived cells for the treatment of urinary tract conditions and methods of making and using the same
AU2008263134B2 (en) * 2007-05-29 2014-06-19 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Bone augmentation utilizing muscle-derived progenitor compositions, and treatments thereof
AU2008307519B9 (en) * 2007-10-04 2014-11-13 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Skeletal muscle augmentation utilizing muscle-derived progenitor compositions, and treatments thereof
CA2734858C (en) 2008-08-18 2019-01-15 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Bone augmentation utilizing muscle-derived progenitor compositions in biocompatible matrix, and treatments thereof
US20130123647A1 (en) 2011-05-03 2013-05-16 The Research Foundation Of State University Of New York Methods Useful in Optimizing the Treatment of Neuropathies and Targeting Tissues with Cosmetic Botulinum Injections
US9878071B2 (en) 2013-10-16 2018-01-30 Purdue Research Foundation Collagen compositions and methods of use
WO2016172365A1 (en) 2015-04-21 2016-10-27 Purdue Research Foundation Office Of Technology Commercialization Cell-collagen-silica composites and methods of making and using the same
EP3615568A4 (en) 2017-04-25 2021-01-20 Purdue Research Foundation 3-dimensional (3d) tissue-engineered muscle for tissue restoration
PL3724319T3 (en) 2017-12-14 2023-07-24 Innovacell Ag Methods for obtaining muscle derived cells
CA3134213A1 (en) 2019-03-22 2020-10-01 Innovacell Ag Methods for obtaining induced smooth muscle cells
EP3778875A1 (en) * 2019-08-14 2021-02-17 MaxiVax SA Immortalized myoblast cell lines and uses thereof
WO2024047234A1 (en) 2022-09-02 2024-03-07 Universität Zürich Injection device
WO2024110320A1 (en) 2022-11-21 2024-05-30 ECOLE POLYTECHNIQUE FéDéRALE DE LAUSANNE System for control of spasticity
WO2024115761A1 (en) 2022-12-01 2024-06-06 Universität Zürich Method of preparing a mass culture of muscle precursor cells (mpcs) and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999056785A2 (en) * 1998-05-01 1999-11-11 University Of Pittsburgh Cell mediated gene delivery using muscle derived cells for treating muscle-and bone-related injury or dysfunction

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4424208A (en) 1982-01-11 1984-01-03 Collagen Corporation Collagen implant material and method for augmenting soft tissue
US4851521A (en) 1985-07-08 1989-07-25 Fidia, S.P.A. Esters of hyaluronic acid
US5266480A (en) 1986-04-18 1993-11-30 Advanced Tissue Sciences, Inc. Three-dimensional skin culture system
US5902741A (en) 1986-04-18 1999-05-11 Advanced Tissue Sciences, Inc. Three-dimensional cartilage cultures
US5510254A (en) 1986-04-18 1996-04-23 Advanced Tissue Sciences, Inc. Three dimensional cell and tissue culture system
US5863531A (en) 1986-04-18 1999-01-26 Advanced Tissue Sciences, Inc. In vitro preparation of tubular tissue structures by stromal cell culture on a three-dimensional framework
US5053050A (en) 1988-04-29 1991-10-01 Samuel Itay Compositions for repair of cartilage and bone
US5130141A (en) * 1988-05-24 1992-07-14 Law Peter K Compositions for and methods of treating muscle degeneration and weakness
US5082670A (en) 1988-12-15 1992-01-21 The Regents Of The University Of California Method of grafting genetically modified cells to treat defects, disease or damage or the central nervous system
US5538722A (en) 1989-06-13 1996-07-23 Stanford University Isolation, growth, differentiation and genetic engineering of human muscle cells
US5045601A (en) 1989-06-13 1991-09-03 Biointerface Technologies, Inc. Pressure-sensitive adhesive compositions suitable for medical uses
CA2045630A1 (en) 1989-11-24 1991-05-25 Lawrence Austin Proliferative action of leukaemia inhibitory factor on satellite cells
US5206028A (en) 1991-02-11 1993-04-27 Li Shu Tung Dense collagen membrane matrices for medical uses
US6497872B1 (en) 1991-07-08 2002-12-24 Neurospheres Holdings Ltd. Neural transplantation using proliferated multipotent neural stem cells and their progeny
CA2133756C (en) 1992-04-06 2000-02-22 Robert A. Ersek Treatment of urological and gastric fluid reflux disorders by injection of micro particles
KR950703643A (en) 1992-09-28 1995-09-20 윌리암 엠. 잭슨 CHITOSAN MATRICES FOR ENCAPSULATED CELLS
JP2995090B2 (en) 1993-03-19 1999-12-27 キユー・メド・アクチエボラーグ Compositions and methods for tissue augmentation
US5709854A (en) 1993-04-30 1998-01-20 Massachusetts Institute Of Technology Tissue formation by injecting a cell-polymeric solution that gels in vivo
US6001654A (en) 1994-01-28 1999-12-14 California Institute Of Technology Methods for differentiating neural stem cells to neurons or smooth muscle cells using TGT-β super family growth factors
US5656478A (en) 1994-02-25 1997-08-12 The Regents Of The University Of California Smooth muscle tissue formation in vivo using cultured smooth muscle cells combined with an extracellular matrix
US6174333B1 (en) 1994-06-06 2001-01-16 Osiris Therapeutics, Inc. Biomatrix for soft tissue regeneration using mesenchymal stem cells
US5516532A (en) 1994-08-05 1996-05-14 Children's Medical Center Corporation Injectable non-immunogenic cartilage and bone preparation
US5594032A (en) 1994-11-10 1997-01-14 Gonzalez-Cadavid; Nestor F. Amelioration of human erectile dysfunction by treatment with iNOS, inducers of iNOS or iNOS cDNA
SG74036A1 (en) 1994-12-13 2000-07-18 Peter K Law Instrument for cell culture
US7141072B2 (en) 1998-10-05 2006-11-28 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Method for promoting regeneration of surface cartilage in a damaged joint using multi-layer covering
US5833978A (en) 1995-03-16 1998-11-10 Universite Laval Method of in vitro preconditioning healthy donor's myoblasts before transplantation thereof in compatible patients suffering of recessive myopathies like muscular dystrophy, for improving transplantation success
US5733337A (en) 1995-04-07 1998-03-31 Organogenesis, Inc. Tissue repair fabric
US6121042A (en) 1995-04-27 2000-09-19 Advanced Tissue Sciences, Inc. Apparatus and method for simulating in vivo conditions while seeding and culturing three-dimensional tissue constructs
US5855610A (en) 1995-05-19 1999-01-05 Children's Medical Center Corporation Engineering of strong, pliable tissues
WO1996039035A1 (en) * 1995-06-06 1996-12-12 Case Western Reserve University Myogenic differentiation of human mesenchymal stem cells
US5591444A (en) 1995-07-28 1997-01-07 Isolagen Technologies, Inc. Use of autologous dermal fibroblasts for the repair of skin and soft tissue defects
US5869041A (en) 1996-01-12 1999-02-09 The Miriam Hospital Delivery of bioactive compounds to an organism
US6200606B1 (en) 1996-01-16 2001-03-13 Depuy Orthopaedics, Inc. Isolation of precursor cells from hematopoietic and nonhematopoietic tissues and their use in vivo bone and cartilage regeneration
US5858351A (en) 1996-01-18 1999-01-12 Avigen, Inc. Methods for delivering DNA to muscle cells using recombinant adeno-associated virus vectors
US5876447A (en) 1996-02-14 1999-03-02 Implantech Associates Silicone implant for facial plastic surgery
US5842477A (en) 1996-02-21 1998-12-01 Advanced Tissue Sciences, Inc. Method for repairing cartilage
US6299905B1 (en) 1996-04-16 2001-10-09 Depuy Orthopaedics, Inc. Bioerodable polymeric adhesives for tissue repair
US5895745A (en) * 1996-09-25 1999-04-20 W.R. Grace & Co.-Conn. Method of thawing cryopreserved cells
US6150338A (en) 1997-02-13 2000-11-21 Albert Einstein College Of Medicine Of Yeshiva University Gene therapy for alleviating erectile dysfunction
US6337184B1 (en) 1997-04-01 2002-01-08 Jeffrey B. Miller Molecular marker for muscle stem cells
US6099832A (en) 1997-05-28 2000-08-08 Genzyme Corporation Transplants for myocardial scars
US6110459A (en) 1997-05-28 2000-08-29 Mickle; Donald A. G. Transplants for myocardial scars and methods and cellular preparations
US20020068048A1 (en) 1997-09-05 2002-06-06 Patrick A. Dreyfus Method for the treatment or diagnosis of human pathologies with disseminated or difficult to access cells or tissues
US6171340B1 (en) 1998-02-27 2001-01-09 Mcdowell Charles L. Method and device for regenerating cartilage in articulating joints
WO1999044643A1 (en) 1998-03-06 1999-09-10 Biosepra Medical Inc. Implantable particles for tissue bulking and the treatment of gastroesophageal reflux disease, urinary incontinence, and skin wrinkles
WO1999046366A1 (en) * 1998-03-13 1999-09-16 Osiris Therapeutics, Inc. Uses for humane non-autologous mesenchymal stem cells
DE69929681T2 (en) 1998-03-18 2006-10-26 Osiris Therapeutics, Inc. MESENCHYMAL STEM CELLS FOR THE PREVENTION AND TREATMENT OF IMMUNE RESPONSES IN TRANSPLANTATIONS
US6866842B1 (en) 1998-05-01 2005-03-15 University Of Pittsburgh Muscle-derived cells (MDCs) for treating muscle-or bone-related injury or dysfunction
US7115417B1 (en) 1998-05-01 2006-10-03 Chancellor Michael B Soft tissue and bone augmentation and bulking utilizing muscle-derived progenito compositions, and treatments thereof
AU3697899A (en) 1998-05-05 1999-11-23 Institut Fur Diagnostikforschung Gmbh An Der Freien Universitat Berlin Diagnostic agent for mr diagnosis
ATE424147T1 (en) 1998-06-05 2009-03-15 Organogenesis Inc BIOTECHNICALLY CREATED VASCULAR PROSTHESIS FOR IMPLANTATION
US6190893B1 (en) 1998-09-18 2001-02-20 Massachusetts Institute Of Technology Electroactive materials for stimulation of biological activity of bone marrow stromal cells
AU1626500A (en) 1998-11-16 2000-06-05 Osiris Therapeutics, Inc. Alginate layer system for chondrogenic differentiation of human mesenchymal stemcells
JP2000287683A (en) 1999-04-08 2000-10-17 Frontier:Kk Muscle-derived component and rna having neuron survival activity
US6328762B1 (en) 1999-04-27 2001-12-11 Sulzer Biologics, Inc. Prosthetic grafts
US6306424B1 (en) 1999-06-30 2001-10-23 Ethicon, Inc. Foam composite for the repair or regeneration of tissue
WO2001019966A2 (en) 1999-09-14 2001-03-22 Children's Medical Center Corporation, The Isolation of muscle-derived stem cells and uses therefor
ES2291228T3 (en) 1999-12-03 2008-03-01 The University Of Leeds REPAIR OF DAMAGED FABRIC.
US6368859B1 (en) 1999-12-29 2002-04-09 Children's Medical Center Corporation Methods and compositions for producing a fascial sling
DK1272204T3 (en) 2000-04-14 2007-09-10 Univ Pittsburgh Enhancement and bulking of soft tissue and bone tissue using muscle derived progenitor cells, preparations thereof and treatment thereof
AU2006202380B2 (en) 2000-04-14 2007-06-21 University Of Pittsburgh Soft tissue and bone augmentation and bulking utilizing muscle-derived progenitor cells, compositions and treatments thereof
CA2407027C (en) 2000-04-20 2011-02-15 Rtp Pharma Inc. Improved water-insoluble drug particle process
FR2810045B1 (en) 2000-06-07 2004-09-03 Assist Publ Hopitaux De Paris METHOD FOR OBTAINING CELLULAR CELLULAR POPULATIONS OF MUSCLE ORIGIN AND USES THEREOF
US20020090389A1 (en) 2000-12-01 2002-07-11 Humes H. David Intravascular blood conditioning device and use thereof
JP4680483B2 (en) 2001-02-23 2011-05-11 ユニバーシティ オブ ピッツバーグ オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション Rapid preparation of stem cell matrix for use in the treatment and repair of tissues and organs
CA2338124C (en) 2001-02-26 2010-08-03 Valerie Dumont Dicianna Self-tanning composition in sheeted substrate
WO2002083864A2 (en) 2001-04-13 2002-10-24 Anterogen Co., Ltd. Methods and reagents for cell transplantation
EP1539934A2 (en) 2002-07-30 2005-06-15 Tigenix N.V. Compositions comprising muscle progenitor cells and uses thereof
WO2004096245A2 (en) 2003-04-25 2004-11-11 The University Of Pittsburgh Muscle derived cells (mdcs) for promoting and enhancing nerve repair and regeneration
NZ553695A (en) 2004-08-16 2009-10-30 Cellres Corp Pte Ltd Isolation of stem/progenitor cells from amniotic membrane of umbilical cord
US20090221644A1 (en) 2005-06-30 2009-09-03 Stuart Edward Bradley Gpcr Agonists
JP5395672B2 (en) 2006-11-28 2014-01-22 ユニバーシティー オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケーション Muscle-derived cells for treating cardiac pathology and methods for making and using the same
AU2007334331B2 (en) 2006-12-18 2014-05-29 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Muscle derived cells for the treatment of gastro-esophageal pathologies and methods of making and using the same
JP5425641B2 (en) 2007-01-11 2014-02-26 ユニバーシティー オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケーション Muscle-derived cells for the treatment of urinary tract conditions and methods of making and using the same
TW200902007A (en) 2007-05-25 2009-01-16 Astrazeneca Ab Spirocyclopropyl piperidine derivatives
AU2008263134B2 (en) 2007-05-29 2014-06-19 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Bone augmentation utilizing muscle-derived progenitor compositions, and treatments thereof
CA2734858C (en) 2008-08-18 2019-01-15 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Bone augmentation utilizing muscle-derived progenitor compositions in biocompatible matrix, and treatments thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999056785A2 (en) * 1998-05-01 1999-11-11 University Of Pittsburgh Cell mediated gene delivery using muscle derived cells for treating muscle-and bone-related injury or dysfunction

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JANKOWSKI RON J ET AL: "Flow cytometric characterization of myogenic cell populations obtained via the preplate technique: Potential for rapid isolation of muscle-derived stem cells.", HUMAN GENE THERAPY, vol. 12, no. 6, 10 April 2001 (2001-04-10), pages 619 - 628, XP002183830, ISSN: 1043-0342 *
QU ZHUQING ET AL: "Identification of muscle-derived stem cells.", MOLECULAR BIOLOGY OF THE CELL, vol. 10, no. SUPPL., November 1999 (1999-11-01), 39th Annual Meeting of the American Society for Cell Biology;Washington, D.C., USA; December 11-15, 1999, pages 246a, XP000982555, ISSN: 1059-1524 *
SMITH J ET AL: "STABLE INTREGRATION OF AN MDX SKELETAL MUSCLE CELL LINE INTO DYSTROPHIC (MDX) SKELETAL MUSCLE: EVIDENCE FOR STEM CELL STATUS", CELL GROWTH AND DIFFERENTIATION, XX, XX, vol. 8, no. 8, August 1997 (1997-08-01), pages 927 - 934, XP000982572 *

Also Published As

Publication number Publication date
CY1108090T1 (en) 2014-02-12
CA2406393A1 (en) 2001-10-25
EP1272204A2 (en) 2003-01-08
US20210145892A1 (en) 2021-05-20
PT1272204E (en) 2007-10-02
JP2012180355A (en) 2012-09-20
US9499791B2 (en) 2016-11-22
JP2003531125A (en) 2003-10-21
AU2001251599B2 (en) 2006-03-02
DE60129007T2 (en) 2008-02-28
US20090098094A1 (en) 2009-04-16
US20160303169A9 (en) 2016-10-20
EP1272204B1 (en) 2007-06-20
DK1272204T3 (en) 2007-09-10
HK1052645A1 (en) 2003-09-26
HK1052645B (en) 2008-03-20
DE60129007D1 (en) 2007-08-02
CA2406393C (en) 2012-10-02
JP5684963B2 (en) 2015-03-18
ATE365045T1 (en) 2007-07-15
US20170209495A1 (en) 2017-07-27
ES2288946T3 (en) 2008-02-01
WO2001078754A2 (en) 2001-10-25
AU5159901A (en) 2001-10-30

Similar Documents

Publication Publication Date Title
WO2001078754A3 (en) Soft tissue and bone augmentation and bulking utilizing muscle-derived progenitor cells, compositions and treatments thereof
SG146691A1 (en) Methods of preparing and using stem cell compositions and kits comprising the same
EP1077254A3 (en) Multiple mesodermal lineage differentiation potentials for adipose tissue-derived stromal cells and uses thereof
NO2014010I2 (en)
MXPA04001334A (en) Materials and methods to promote repair of nerve tissue.
WO2003060085A3 (en) Mammalian neural stem cells, compositions and uses thereof
IL159895A0 (en) Methods of generating human cardiac cells and tissues and uses thereof
WO2005038012A3 (en) Cartilage and bone repair and regeneration using postpartum-derived cells
NO20033177L (en) Injectable depot preparations and their use
EP2311469A3 (en) Methods and compositions for tissue regeneration
WO2005061019A3 (en) Methods and composition for soft tissue feature reconstruction
AU2001270408A1 (en) Intervertebral disc
MX9803992A (en) Methods of increasing lean tissue mass using ob protein compositions.
WO2001038303A3 (en) Vitamin d analogues
WO2008066886A3 (en) Muscle derived cells for the treatment of cardiac pathologies and methods of making and using the same
WO2002007749A3 (en) Device providing regulated growth factor delivery for the regeneration of peripheral nerves
WO2001094541A3 (en) Human mesenchymal progenitor cell
AU2003296977A1 (en) Methods and compositions using compounds from fetal cells and tissues to improve condition of skin
EP2364708A3 (en) Pharmaceutical composition comprising a ClC-2 channel opener
AU2002366433A1 (en) Methods and compositions for treating metabolic bone diseases relating to human endokine alpha
WO2004033660A3 (en) Gene expression profiling from ffpe samples
WO2001094586A3 (en) Non-agonistic antibodies to human gp39, compositions containing, and therapeutic use thereof
GB2454154A (en) Aglet for attachment to a graft material
WO2003029432A3 (en) Human mesenchymal progenitor cell
WO2002062301A3 (en) Method and composition for rejuvinating cells, tissues, organs, hair and nails

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2406393

Country of ref document: CA

Ref document number: 2001251599

Country of ref document: AU

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 576054

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2001924998

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001924998

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 2001924998

Country of ref document: EP